Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NTLA Stock Forecast 2026-2027
$12.85
Current Price
$1.52B
Market Cap
Buy 14
Hold 9
Sell 2
Wall St Analyst Ratings
Distance to NTLA Price Targets
+724.9%
To High Target of $106.00
+47.9%
To Median Target of $19.00
-61.1%
To Low Target of $5.00
NTLA Price Momentum
-4.4%
1 Week Change
+8.3%
1 Month Change
+39.4%
1 Year Change
+42.9%
Year-to-Date Change
-54.5%
From 52W High of $28.25
+117.8%
From 52W Low of $5.90
📊 TOP ANALYST CALLS
Did NTLA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Intellia is one of their latest high-conviction picks.
Latest NTLA Stock Price Targets & Analyst Predictions
Based on our analysis of 37 Wall Street analysts, NTLA has a bullish consensus with a median price target of $19.00 (ranging from $5.00 to $106.00). The overall analyst rating is Buy (7.8/10). Currently trading at $12.85, the median forecast implies a 47.9% upside. This outlook is supported by 14 Buy, 9 Hold, and 2 Sell ratings.
Conversely, the most conservative target is provided by Brian Cheng at JP Morgan, suggesting a 61.1% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NTLA Analyst Ratings
14
Buy
9
Hold
2
Sell
NTLA Price Target Range
Low
$5.00
Average
$19.00
High
$106.00
Current: $12.85
Latest NTLA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NTLA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 4, 2026 | Jones Trading | Debanjana Chatterjee | Buy | Upgrade | $29.00 |
| Mar 3, 2026 | Citizens | Silvan Turkcan | Market Outperform | Maintains | $28.00 |
| Mar 3, 2026 | Wells Fargo | Yanan Zhu | Equal-Weight | Maintains | $15.00 |
| Mar 3, 2026 | RBC Capital | Luca Issi | Sector Perform | Maintains | $15.00 |
| Mar 3, 2026 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $48.00 |
| Mar 3, 2026 | Leerink Partners | Mani Foroohar | Outperform | Maintains | $29.00 |
| Mar 3, 2026 | HC Wainwright & Co. | Mitchell S. Kapoor | Buy | Maintains | $30.00 |
| Mar 2, 2026 | Chardan Capital | Geulah Livshits | Buy | Maintains | $27.00 |
| Feb 27, 2026 | Chardan Capital | Geulah Livshits | Buy | Maintains | $26.00 |
| Jan 28, 2026 | HC Wainwright & Co. | Mitchell S. Kapoor | Buy | Maintains | $25.00 |
| Nov 12, 2025 | Wolfe Research | Andy Chen | Peer Perform | Downgrade | $N/A |
| Nov 11, 2025 | Jones Trading | Debanjana Chatterjee | Hold | Downgrade | $N/A |
| Nov 11, 2025 | Evercore ISI Group | Jonathan Miller | In-Line | Downgrade | $8.00 |
| Nov 10, 2025 | Truist Securities | Joon Lee | Buy | Reiterates | $14.00 |
| Nov 10, 2025 | HC Wainwright & Co. | Mitchell S. Kapoor | Buy | Maintains | $15.00 |
| Nov 7, 2025 | Wedbush | David Nierengarten | Neutral | Maintains | $7.00 |
| Nov 7, 2025 | Citizens | Silvan Tuerkcan | Market Outperform | Maintains | $21.00 |
| Nov 7, 2025 | JP Morgan | Brian Cheng | Underweight | Downgrade | $5.00 |
| Nov 7, 2025 | RBC Capital | Luca Issi | Sector Perform | Maintains | $9.00 |
| Nov 7, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $26.00 |
Intellia Therapeutics Inc. (NTLA) Competitors
The following stocks are similar to Intellia based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Intellia Therapeutics Inc. (NTLA) Financial Data
Intellia Therapeutics Inc. has a market capitalization of $1.52B with a P/E ratio of -3.4x. The company generates $67.67M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +78.8% quarter-over-quarter, while maintaining an operating margin of -428.9% and return on equity of -53.5%.
Valuation Metrics
Market Cap
$1.52B
Enterprise Value
$1.23B
P/E Ratio
-3.4x
PEG Ratio
0.1x
Price/Sales
23.0x
Growth & Margins
Revenue Growth (YoY)
+78.8%
Gross Margin
N/A
Operating Margin
-428.9%
Net Margin
0.0%
EPS Growth
+78.8%
Financial Health
Cash/Price Ratio
+29.6%
Current Ratio
5.1x
Debt/Equity
13.9x
ROE
-53.5%
ROA
-27.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Intellia Therapeutics Inc. (NTLA) Business Model
About Intellia Therapeutics Inc.
What They Do
Develops curative genome editing therapies.
Business Model
The company operates by utilizing CRISPR/Cas9 technology to create single-treatment therapies that permanently edit and correct disease-associated genes. Intellia Therapeutics generates revenue through the advancement of its clinical-stage programs targeting genetic disorders and cancers, potentially leading to partnerships and licensing agreements in the biopharmaceutical sector.
Additional Information
Founded in 2014 and headquartered in Cambridge, Massachusetts, Intellia is a key player in precision genomic medicine. Its pipeline includes treatments for transthyretin amyloidosis and hereditary angioedema, in addition to engineered cell therapies for various cancers and autoimmune diseases.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
403
CEO
Dr. John M. Leonard M.D.
Country
United States
IPO Year
2016
Website
www.intelliatx.comIntellia Therapeutics Inc. (NTLA) Latest News & Analysis
Latest News
Quick Summary
Intellia Therapeutics is overcoming a recent regulatory setback, but its stock continues to face multiple potential challenges.
Why It Matters
Intellia's management of a regulatory setback signals resilience, but ongoing potential issues could impact stock performance and investor confidence.
Source: The Motley Fool
Market Sentiment:
Neutral
Quick Summary
Intellia Therapeutics (Nasdaq: NTLA) awarded inducement grants to six new employees on March 1, 2026, as part of its 2024 Inducement Plan to enhance recruitment efforts.
Why It Matters
Intellia's inducement grants signal growth and expansion, potentially enhancing talent acquisition, innovation, and future product development, affecting long-term value and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Intellia Therapeutics announced that the FDA lifted a clinical hold on its late-stage trial for an experimental gene therapy targeting heart disease.
Why It Matters
The FDA lifting the clinical hold allows Intellia to advance its gene therapy, potentially increasing its market value and offering new investment opportunities in biotech.
Source: Reuters
Market Sentiment:
Positive
Quick Summary
Intellia Therapeutics (NASDAQ: NTLA) shares rose after the FDA lifted the clinical hold on its MAGNITUDE Phase 3 trial.
Why It Matters
The FDA lifting the clinical hold boosts Intellia's prospects for the MAGNITUDE trial, indicating potential advancements in its therapies, which can positively impact stock performance.
Source: Benzinga
Market Sentiment:
Positive
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
11 days ago
Quick Summary
Intellia Therapeutics announced that the FDA has lifted the clinical hold on its IND for the Phase 3 trial of nexiguran ziclumeran (nex-z) for treating ATTR-CM.
Why It Matters
The FDA lifting the clinical hold allows Intellia to advance its Phase 3 trial for a potentially groundbreaking treatment, which could significantly boost its market position and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Intellia Therapeutics (Nasdaq: NTLA) presented four posters at the 2026 AAAAI Annual Meeting, highlighting advancements in CRISPR gene editing and related technologies.
Why It Matters
Intellia's presentation at a key medical conference highlights its advancements in CRISPR technology, potentially influencing its market position and investor confidence in future growth.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About NTLA Stock
What is Intellia Therapeutics Inc.'s (NTLA) stock forecast for 2026?
Based on our analysis of 37 Wall Street analysts, Intellia Therapeutics Inc. (NTLA) has a median price target of $19.00. The highest price target is $106.00 and the lowest is $5.00.
Is NTLA stock a good investment in 2026?
According to current analyst ratings, NTLA has 14 Buy ratings, 9 Hold ratings, and 2 Sell ratings. The stock is currently trading at $12.85. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NTLA stock?
Wall Street analysts predict NTLA stock could reach $19.00 in the next 12 months. This represents a 47.9% increase from the current price of $12.85. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Intellia Therapeutics Inc.'s business model?
The company operates by utilizing CRISPR/Cas9 technology to create single-treatment therapies that permanently edit and correct disease-associated genes. Intellia Therapeutics generates revenue through the advancement of its clinical-stage programs targeting genetic disorders and cancers, potentially leading to partnerships and licensing agreements in the biopharmaceutical sector.
What is the highest forecasted price for NTLA Intellia Therapeutics Inc.?
Price targets from Wall Street analysts for NTLA are not currently available. The stock is trading at $12.85.
What is the lowest forecasted price for NTLA Intellia Therapeutics Inc.?
The lowest price target for NTLA is $5.00 from Brian Cheng at JP Morgan, which represents a -61.1% decrease from the current price of $12.85.
What is the overall NTLA consensus from analysts for Intellia Therapeutics Inc.?
The overall analyst consensus for NTLA is bullish. Out of 37 Wall Street analysts, 14 rate it as Buy, 9 as Hold, and 2 as Sell, with a median price target of $19.00.
How accurate are NTLA stock price projections?
Stock price projections, including those for Intellia Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 13, 2026 2:36 PM UTC